Incyte INCY announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

Incyte (NASDAQ:INCY) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

The U.S. FDA is launching a program under which its commissioner can issue vouchers to companies he finds are aligned with national priorities to shorten their review time for a drug application to ...

Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- ...

Amtagvi ® and its accompanying design marks, Proleukin ®, Iovance ®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other ...

A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved ...

SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating ...

Iovance Therapeutics(NASDAQ: IOVA) currently has one product on the market, Amtagvi, which is approved as a second-line treatment for advanced melanoma. Amtagvi is the first T-cell therapy approved by ...